Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
Wietske Kievit*, Noortje van Herwaarden, Frank H. J. van den Hoogen, Ronald F. van Vollenhoven, Johannes W. J. Bijlsma, Bart J. F. van den Bemt, Aatke van der Maas, Alfons A. den Broeder
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study'. Together they form a unique fingerprint.